:E-6837

{{Chembox

| ImageFile = E_6837.svg

| ImageSize =

| ImageAlt =

| PIN = 5-Chloro-N-{3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}naphthalene-2-sulfonamide

| OtherNames = E 6837

|Section1={{Chembox Identifiers

| CASNo = 528859-61-2

| CASNo_Ref = {{cascite|correct|CAS}}

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 4AXX8P95BU

| ChEMBL = 175835

| PubChem = 6918836

| ChemSpiderID = 5294027

| SMILES = CN(C)CCC1=CNC2=C1C=C(C=C2)NS(=O)(=O)C3=CC4=C(C=C3)C(=CC=C4)Cl

| StdInChI = 1S/C22H22ClN3O2S/c1-26(2)11-10-16-14-24-22-9-6-17(13-20(16)22)25-29(27,28)18-7-8-19-15(12-18)4-3-5-21(19)23/h3-9,12-14,24-25H,10-11H2,1-2H3

| StdInChIKey = OOIQBABUMXSCPC-UHFFFAOYSA-N

| MeSHName = C500059

}}

|Section2={{Chembox Properties

| Formula = C₂₂H₂₂ClN₃O₂S

| MolarMass = 427.95 g/mol

| Appearance =

| Density =

| MeltingPt =

| BoilingPt =

| Solubility = }}

|Section3={{Chembox Hazards

| MainHazards =

| FlashPt =

| AutoignitionPt = }}

}}

E-6837 is an orally active, 5-HT₆ agonist developed in an attempt to create an anti-obesity medication.

In cell lines expressing rat 5-HT₆ receptors, it acted as a partial agonist (on presumed silent receptors), while it acted as a full agonist on human 5-HT₆ receptors (which are constitutively active).

Oral administration of E-6837 reduced food intake, but only transiently. In rats, twice daily administration of E-6837 over the course of 4 weeks resulted in a 15.7% reduction in body weight, compared to 11% reduction for sibutramine. This weight loss remained significant for E-6837 after a 43-day withdrawal period, whereas the weight difference was non-significant for sibutramine (i.e., sibutramine had a rebound effect while E-6837 did not), and this weight loss was found to be due to a loss of fat mass. The reduction in fat mass in E-6837 treated animals was associated with a 50% decrease in plasma leptin levels, and also reduced glucose and insulin levels in plasma after a glucose tolerance test. This indicates that weight loss from E-6837 is associated with improved insulin sensitivity, and thus, better glycemic control.{{cite journal|last=Fisas|first=Angels|title=Chronic 5-HT6 receptor modulation by E-6837 induces hypophagia and sustained weight loss in diet-induced obese rats|journal=British Journal of Pharmacology|date=August 2006|volume=148|issue=7|pages=973–983|pmid=16783408|doi=10.1038/sj.bjp.0706807|pmc=1751931}}{{cite journal|last=Kirkpatrick|first=Peter|title=Anti-obesity drugs: Fighting fat|journal=Nature Reviews Drug Discovery|date=1 August 2006|volume=5|issue=8|pages=634|doi=10.1038/nrd2123|s2cid=35924150|doi-access=free}}{{cite journal|last=Garfield|first=A. S.|author2=Heisler, L. K.|title=Pharmacological targeting of the serotonergic system for the treatment of obesity|journal=The Journal of Physiology|date=24 November 2008|volume=587|issue=1|pages=49–60|doi=10.1113/jphysiol.2008.164152|pmid=19029184|pmc=2670022}}

One proposed mechanism of action is that E-6837 acts on neurons in the hypothalamus, which has shown significant levels of 5-HT₆ receptor mRNA. The hypothalamus is one key structure involved in regulating food intake.